GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Stock Based Compensation

Allakos (STU:37Z) Stock Based Compensation : €34.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Allakos Stock Based Compensation?

Allakos's Stock Based Compensation for the three months ended in Mar. 2024 was €5.71 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was €34.00 Mil.


Allakos Stock Based Compensation Historical Data

The historical data trend for Allakos's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Stock Based Compensation Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial 14.18 27.50 44.99 40.74 37.80

Allakos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.97 9.06 9.87 9.35 5.71

Allakos Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €34.00 Mil.


Allakos Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Allakos's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Allakos (STU:37Z) Business Description

Industry
Traded in Other Exchanges
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (STU:37Z) Headlines

No Headlines